Scarica l'app Stockscreener
0.718
4.69%
-0.0353
Dopo l'orario di chiusura:
.70
-0.018
-2.51%
Precedente Chiudi:
$0.7533
Aprire:
$0.7659
Volume 24 ore:
276.98K
Relative Volume:
1.28
Capitalizzazione di mercato:
$35.81M
Reddito:
-
Utile/perdita netta:
$-17.78M
Rapporto P/E:
-1.3074
EPS:
-0.5492
Flusso di cassa netto:
$-10.52M
1 W Prestazione:
-17.47%
1M Prestazione:
-23.13%
6M Prestazione:
-64.28%
1 anno Prestazione:
-88.42%
Intervallo 1D:
$0.7096
$0.7775
Intervallo di 1 settimana:
$0.7096
$0.8973
Portata 52W:
$0.7013
$6.70
Fibrobiologics Inc Stock (FBLG) Company Profile
Nome
Fibrobiologics Inc
Settore
Industria
Telefono
281-671-5150
Indirizzo
455 E. MEDICAL CENTER BLVD, HOUSTON
Confronta FBLG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.718 | 35.81M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-24 | Iniziato | Maxim Group | Buy |
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
Fibrobiologics closes third $5 mln tranche of $25 mln financing - marketscreener.com
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing - GlobeNewswire
FibroBiologics Raises $25M to Launch Breakthrough Diabetic Foot Ulcer Treatment Trial - Stock Titan
FibroBiologics to Present Company Update and Research Advances at BIO International Convention 2025 - Nasdaq
FibroBiologics to Present at the BIO International Convention 2025 - GlobeNewswire
Clinical Trial Alert: FibroBiologics Unveils Groundbreaking Fibroblast Treatment for Chronic Disease at BIO 2025 - Stock Titan
FibroBiologics, Inc. (NASDAQ:FBLG) Receives Consensus Rating of “Buy” from Brokerages - Defense World
FibroBiologics names new CFO after going public last year - The Business Journals
FibroBiologics appoints new CFO amid clinical trials By Investing.com - Investing.com South Africa
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer, Effective June 9, 2025 - marketscreener.com
FibroBiologics appoints Jason Davis as CFO - TipRanks
FibroBiologics Appoints Jason Davis As CFO - Nasdaq
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer to Drive Growth and Clinical Development - Nasdaq
FibroBiologics appoints new CFO amid clinical trials - Investing.com
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer - GlobeNewswire
FibroBiologics Taps Former Virax IPO Leader as CFO Ahead of Critical Clinical Trials - Stock Titan
Jane Street Group LLC Acquires 49,222 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Top Executive Makes Bold Move with Major Stock Purchase in FibroBiologics! - TipRanks
FibroBiologics, Inc. (NASDAQ:FBLG) Receives $13.00 Consensus PT from Analysts - Defense World
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis - Research Tree
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis… - Zacks Small Cap Research
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting - GlobeNewswire
D. Boral Capital Reiterates Buy Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
FibroBiologics Presents Research on Human Dermal Fibroblast Spheroids for Psoriasis Therapy at SID Annual Meeting - Nasdaq
Revolutionary Fibroblast Treatment Shows Promise for Long-lasting Psoriasis Relief, New Data Reveals - Stock Titan
Raymond James Financial Inc. Takes $37,000 Position in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
FibroBiologics, Inc. Reports First Quarter 2025 Financial Results and Operational Milestones - Nasdaq
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Earnings: Net Loss Drops 41%, Clinical Trial Launch Set for Breakthrough Wound Treatment - Stock Titan
FibroBiologics, Inc. SEC 10-Q Report - TradingView
FibroBiologics (FBLG) Projected to Post Earnings on Tuesday - Defense World
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn Inc.
Biotech Veteran Robert Hoffman Joins CytoDyn as CFO: Key Strategic Hire for Leronlimab Developer - Stock Titan
Fibrobiologics Inc Says On May 2, Robert E. Hoffman Resigns As Interim CFO Effective May 14, 2025SEC Filing - marketscreener.com
FibroBiologics CFO Robert Hoffman Resigns - TipRanks
FibroBiologics Presents at the ThymUS 2025 Meeting - GlobeNewswire
FibroBiologics Research Scientist Presents Innovative Thymus Organoid Development at ThymUS 2025 Meeting - Nasdaq
Revolutionary Thymus Organoid Breakthrough: FibroBiologics Reveals New T-Cell Generation Method - Stock Titan
FibroBiologics, Inc. (NASDAQ:FBLG) Shares Acquired by Cerity Partners LLC - Defense World
FibroBiologics Inc Inc. (FBLG) Price Performance: A Technical Analysis Perspective - investchronicle.com
O Shaughnessy Asset Management LLC Acquires New Position in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Raymond James Financial Inc. Invests $37,000 in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital - Defense World
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean - GlobeNewswire
Revolutionary Cell Therapy: FibroBiologics Unveils Multi-Disease Treatment Platform in Rome - Stock Titan
Houston Biotechnology Company Brings Manufacturing Ops Home With New Facility - Bisnow
Fibrobiologics stock plunges to 52-week low at $0.8 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.8 amid market challenges - Investing.com India
FibroBiologics opens cell therapy manufacturing space ahead of clinical trials - The Business Journals
OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR - Yahoo Finance
Fibrobiologics Inc Azioni (FBLG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fibrobiologics Inc Azioni (FBLG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | Chief Executive Officer |
Aug 12 '24 |
Buy |
1.91 |
8,500 |
16,269 |
6,056,647 |
| Khoja Hamid | Chief Scientific Officer |
Aug 12 '24 |
Buy |
1.90 |
10,000 |
19,000 |
11,250 |
2.13%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):